Background: Skeletal complications frequently complicate the natural history of prostate cancer with metastatic bone disease. Androgen deprivation therapy (ADT), the mainstay of therapy for advanced prostate cancer, induces osteoporosis and may cause adverse skeletal related events (SRE) irrespective of disease progression in bone. SRE, however, are relatively uncommon until the tumor is responsive to ADT but they are more frequent when the tumor become hormone refractory. The relative contribution of ADT in predisposing SRE in hormone refractory stage is totally unknown. Methods: From July 1990 to September 2003, 205 prostate cancer patients with hormone refractory disease were treated and followed in our Institution. Eighty-three of them (41.0%) underwent SRE defined as vertebra collapses (20.0%), bone fractures (12.7%), spinal cord compression (8.0%). SRE occurred before hormone refractoriness in 8 patients (3.9%). Results: Hormone refractory patients destined to undergo SRE had at baseline conditions greater bone pain (p=0.002), greater values of serum bone alkaline phosphatase (p<0.01), and urinary N-telopeptide (p=0.02) than their counterpart. There was no difference in serum calcium levels and serum PSA between the 2 groups. The distribution of SRE did not differ in patients with blastic bone lesions (40.5%) as opposed to those with lytic/mixed bone lesions (53.7%). Stratifyfing patients according to disease extent in bone, the distribution of SRE was 31.7% in patients with 3 bone lesions, 40.5% in patients with 3–6 bone lesions and 53.6% in patients with > 6 bone lesions (p=0.01). Median duration of ADT (range) was 22.9 months (1.1–138.) in hormone refractory patients destined to undergo SRE and 25.9 months (1.0–211) in hormone refractory patients who did not develop SRE (p=n.s.). Conclusions: the occurence of SRE in hormone refractory prostate cancer with metastatic bone disease is significantly influenced by tumor load in bone, levels of bone turnover markers, but not by the duration of androgen deprivation therapy
The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy
BERRUTI, Alfredo;TAMPELLINI, MARCO;DOGLIOTTI, Luigi
2004-01-01
Abstract
Background: Skeletal complications frequently complicate the natural history of prostate cancer with metastatic bone disease. Androgen deprivation therapy (ADT), the mainstay of therapy for advanced prostate cancer, induces osteoporosis and may cause adverse skeletal related events (SRE) irrespective of disease progression in bone. SRE, however, are relatively uncommon until the tumor is responsive to ADT but they are more frequent when the tumor become hormone refractory. The relative contribution of ADT in predisposing SRE in hormone refractory stage is totally unknown. Methods: From July 1990 to September 2003, 205 prostate cancer patients with hormone refractory disease were treated and followed in our Institution. Eighty-three of them (41.0%) underwent SRE defined as vertebra collapses (20.0%), bone fractures (12.7%), spinal cord compression (8.0%). SRE occurred before hormone refractoriness in 8 patients (3.9%). Results: Hormone refractory patients destined to undergo SRE had at baseline conditions greater bone pain (p=0.002), greater values of serum bone alkaline phosphatase (p<0.01), and urinary N-telopeptide (p=0.02) than their counterpart. There was no difference in serum calcium levels and serum PSA between the 2 groups. The distribution of SRE did not differ in patients with blastic bone lesions (40.5%) as opposed to those with lytic/mixed bone lesions (53.7%). Stratifyfing patients according to disease extent in bone, the distribution of SRE was 31.7% in patients with 3 bone lesions, 40.5% in patients with 3–6 bone lesions and 53.6% in patients with > 6 bone lesions (p=0.01). Median duration of ADT (range) was 22.9 months (1.1–138.) in hormone refractory patients destined to undergo SRE and 25.9 months (1.0–211) in hormone refractory patients who did not develop SRE (p=n.s.). Conclusions: the occurence of SRE in hormone refractory prostate cancer with metastatic bone disease is significantly influenced by tumor load in bone, levels of bone turnover markers, but not by the duration of androgen deprivation therapy
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
